127 related articles for article (PubMed ID: 37573702)
21. Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.
Chen M; Li Q; Xu Y; Zhao J; Zhang L; Wei L; Zhong W; Wang M
Thorac Cancer; 2020 Jul; 11(7):1955-1962. PubMed ID: 32468726
[TBL] [Abstract][Full Text] [Related]
22. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
23. Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres.
Brown LJ; da Silva IP; Moujaber T; Gao B; Hui R; Gurney H; Carlino M; Nagrial A
Cancer Med; 2023 Mar; 12(6):6788-6801. PubMed ID: 36404632
[TBL] [Abstract][Full Text] [Related]
24. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
[TBL] [Abstract][Full Text] [Related]
25. Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland.
Allmann V; Dyntar D; Lehnick D; Dressler M; Zeidler K; Niederberger P; Godau J; Diebold J; Gautschi O
Swiss Med Wkly; 2023 Jan; 153():40039. PubMed ID: 36787492
[TBL] [Abstract][Full Text] [Related]
26. Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy: Single Center Experience of Management and Drug Rechallenge.
Manohar S; Ghamrawi R; Chengappa M; Goksu BNB; Kottschade L; Finnes H; Dronca R; Leventakos K; Herrmann J; Herrmann SM
Kidney360; 2020 Jan; 1(1):16-24. PubMed ID: 35372854
[TBL] [Abstract][Full Text] [Related]
27. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.
Cortazar FB; Kibbelaar ZA; Glezerman IG; Abudayyeh A; Mamlouk O; Motwani SS; Murakami N; Herrmann SM; Manohar S; Shirali AC; Kitchlu A; Shirazian S; Assal A; Vijayan A; Renaghan AD; Ortiz-Melo DI; Rangarajan S; Malik AB; Hogan JJ; Dinh AR; Shin DS; Marrone KA; Mithani Z; Johnson DB; Hosseini A; Uprety D; Sharma S; Gupta S; Reynolds KL; Sise ME; Leaf DE
J Am Soc Nephrol; 2020 Feb; 31(2):435-446. PubMed ID: 31896554
[TBL] [Abstract][Full Text] [Related]
28. Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
Sukari A; Nagasaka M; Alhasan R; Patel D; Wozniak A; Ramchandren R; Vaishampayan U; Weise A; Flaherty L; Jang H; Kim S; Gadgeel S
Anticancer Res; 2019 Feb; 39(2):781-790. PubMed ID: 30711957
[TBL] [Abstract][Full Text] [Related]
29. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy and influencing factors of immunotherapy combined with chemotherapy and bevacizumab in patients with non-small cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitors treatment failure].
Wang C; Li Y; Guan Y; Yang SJ; Yin JC; Zhang CF; Guo QS; Shi WN
Zhonghua Yi Xue Za Zhi; 2023 Apr; 103(16):1210-1216. PubMed ID: 37087404
[No Abstract] [Full Text] [Related]
31. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study.
Luciani A; Marra A; Toschi L; Cortinovis D; Fava S; Filipazzi V; Tuzi A; Cerea G; Rossi S; Perfetti V; Rossi A; Giannetta L; Sala L; Finocchiaro G; Pizzutilo EG; Carelli S; Agustoni F; Cergnul M; Zonato S; Siena S; Bidoli P; Ferrari D
Clin Lung Cancer; 2020 Nov; 21(6):e567-e571. PubMed ID: 32591311
[TBL] [Abstract][Full Text] [Related]
32. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
33. Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study.
Tiu BC; Strohbehn IA; Zhao S; Ouyang T; Hanna P; Wang Q; Gupta S; Leaf DE; Reynolds KL; Sise ME
Oncologist; 2023 Jun; 28(6):e379-e390. PubMed ID: 36821637
[TBL] [Abstract][Full Text] [Related]
34. Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis.
Kanbay M; Yildiz AB; Siriopol D; Vehbi S; Hasbal NB; Kesgin YE; Celayir M; Selcukbiricik F; Covic A; Perazella MA
Int Urol Nephrol; 2023 Apr; 55(4):1025-1032. PubMed ID: 36282399
[TBL] [Abstract][Full Text] [Related]
35. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy.
Baker ML; Yamamoto Y; Perazella MA; Dizman N; Shirali AC; Hafez N; Weinstein J; Simonov M; Testani JM; Kluger HM; Cantley LG; Parikh CR; Wilson FP; Moledina DG
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35354588
[TBL] [Abstract][Full Text] [Related]
36. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
Park JH; You GL; Ahn MJ; Kim SW; Hong MH; Han JY; Ock CY; Lee JS; Oh IJ; Lee SY; Kim CH; Min YJ; Choi YH; Ryu JS; Park SH; Ahn HK; Shim BY; Lee KH; Lee SY; Kim JS; Yi J; Choi SK; An H; Kang JH
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2459-2469. PubMed ID: 33523301
[TBL] [Abstract][Full Text] [Related]
37. Acute kidney injury in idiopathic membranous nephropathy with nephrotic syndrome.
Chen T; Zhou Y; Chen X; Chen B; Pan J
Ren Fail; 2021 Dec; 43(1):1004-1011. PubMed ID: 34157952
[TBL] [Abstract][Full Text] [Related]
38. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
[TBL] [Abstract][Full Text] [Related]
39. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors.
Guven DC; Ozbek DA; Sahin TK; Kavgaci G; Aksun MS; Erul E; Yildirim HC; Chalabiyev E; Cebroyilov C; Yildirim T; Dizdar O; Aksoy S; Yalcin S; Kilickap S; Erman M; Arici M
Anticancer Drugs; 2023 Jul; 34(6):783-790. PubMed ID: 36729111
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice.
Ahn BC; Pyo KH; Xin CF; Jung D; Shim HS; Lee CY; Park SY; Yoon HI; Hong MH; Cho BC; Kim HR
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1613-1623. PubMed ID: 30911841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
